Frontiers in Pharmacology (Nov 2022)
Associations of HLA-A and HLA-B with vancomycin-induced drug reaction with eosinophilia and systemic symptoms in the Han-Chinese population
- Chuang-Wei Wang,
- Chuang-Wei Wang,
- Chuang-Wei Wang,
- Chuang-Wei Wang,
- Chuang-Wei Wang,
- Wei-Chen Lin,
- Wei-Chen Lin,
- Wei-Ti Chen,
- Wei-Ti Chen,
- Wei-Ti Chen,
- Chun-Bing Chen,
- Chun-Bing Chen,
- Chun-Bing Chen,
- Chun-Bing Chen,
- Chun-Bing Chen,
- Chun-Bing Chen,
- Chun-Bing Chen,
- Chun-Wei Lu,
- Chun-Wei Lu,
- Chun-Wei Lu,
- Chun-Wei Lu,
- Chun-Wei Lu,
- Hsin-Han Hou,
- Rosaline Chung-Yee Hui,
- Rosaline Chung-Yee Hui,
- Jennifer Wu,
- Jennifer Wu,
- Jennifer Wu,
- Chih-Jung Chang,
- Chih-Jung Chang,
- Ya-Ching Chang,
- Ya-Ching Chang,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Wen-Hung Chung,
- Taiwan Severe Cutaneous Adverse Reaction Consortium
Affiliations
- Chuang-Wei Wang
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan
- Chuang-Wei Wang
- Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan
- Chuang-Wei Wang
- Chang Gung Immunology Consortium, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan
- Chuang-Wei Wang
- Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China
- Chuang-Wei Wang
- College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Wei-Chen Lin
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan
- Wei-Chen Lin
- Department of Medical Education, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
- Wei-Ti Chen
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan
- Wei-Ti Chen
- Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China
- Wei-Ti Chen
- College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Chun-Bing Chen
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan
- Chun-Bing Chen
- Chang Gung Immunology Consortium, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan
- Chun-Bing Chen
- Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China
- Chun-Bing Chen
- College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Chun-Bing Chen
- Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan
- Chun-Bing Chen
- Immune-Oncology Center of Excellence, Chang Gung Memorial Hospital, Linkou, Taiwan
- Chun-Bing Chen
- Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Chun-Wei Lu
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan
- Chun-Wei Lu
- Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China
- Chun-Wei Lu
- College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Chun-Wei Lu
- Immune-Oncology Center of Excellence, Chang Gung Memorial Hospital, Linkou, Taiwan
- Chun-Wei Lu
- Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Hsin-Han Hou
- 0Graduate Institute of Oral Biology, School of Dentistry, College of Medicine, National Taiwan University, Taipei, Taiwan
- Rosaline Chung-Yee Hui
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan
- Rosaline Chung-Yee Hui
- College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Jennifer Wu
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan
- Jennifer Wu
- College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Jennifer Wu
- Immune-Oncology Center of Excellence, Chang Gung Memorial Hospital, Linkou, Taiwan
- Chih-Jung Chang
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan
- Chih-Jung Chang
- 1Central Research Laboratory, Department of Dermatology and Xiamen Chang Gung Allergology Consortium, Xiamen Chang Gung Hospital, School of Medicine, Huaqiao University, Xiamen, China
- Ya-Ching Chang
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan
- Ya-Ching Chang
- College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Wen-Hung Chung
- Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan
- Wen-Hung Chung
- Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan
- Wen-Hung Chung
- Chang Gung Immunology Consortium, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan
- Wen-Hung Chung
- Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China
- Wen-Hung Chung
- College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Wen-Hung Chung
- Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan
- Wen-Hung Chung
- Immune-Oncology Center of Excellence, Chang Gung Memorial Hospital, Linkou, Taiwan
- Wen-Hung Chung
- 2Department of Dermatology, Beijing Tsinghua Chang Gung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China
- Wen-Hung Chung
- 3Department of Dermatology, Ruijin Hospital School of Medicine, Shanghai Jiao Tong University, Shanghai, China
- Wen-Hung Chung
- 4Genomic Medicine Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan
- Taiwan Severe Cutaneous Adverse Reaction Consortium
- DOI
- https://doi.org/10.3389/fphar.2022.954596
- Journal volume & issue
-
Vol. 13
Abstract
Vancomycin is a commonly used antibiotic; however, it can cause life-threatening severe cutaneous adverse reactions, such as drug reaction with eosinophilia and systemic symptoms (DRESS). A previous study has reported a strong association between HLA-A*32:01 and vancomycin-induced DRESS in European ethnicity. Herein, we aim to investigate the genetic predisposition of vancomycin-induced DRESS in the Han-Chinese population. In this study, we enrolled a total of 26 patients with vancomycin-induced DRESS, 1,616 general population controls, and 51 subjects tolerant to vancomycin. In vitro granulysin-based lymphocyte activation tests (LAT) were conducted among 6 vancomycin-induced DRESS patients who were concomitantly receiving other medicines. HLA-A and HLA-B genotypes were determined by sequencing-based typing. Our results found that vancomycin-induced DRESS was associated with HLA-A*32:01 [odds ratio (OR) = 7.8, 95% confidence interval (CI) = 1.7–35.8; p-value = 0.035], HLA-B*07:05 (OR = 32.3, 95% CI = 2.8–367.7; p-value = 0.047), HLA-B*40:06 (OR = 4.7, 95% CI = 1.3–16.1; p-value = 0.036) and HLA-B*67:01 (OR = 44.8, 95% CI = 7.2–280.4; p-value = 0.002) when comparing the vancomycin-induced DRESS patients with the general population controls. LAT results showed that granulysin significantly increased in the vancomycin-induced DRESS patients upon vancomycin stimulation (4.7 ± 3.7 fold increased), but not upon other co-medicines. This study identified that, in addition to HLA-A*32:01, HLA-B*07:05, HLA-B*40:06, and HLA-B*67:01 were also genetic markers for vancomycin-induced DRESS in the Han-Chinese population. Associations of ethnic variances in HLA with vancomycin-DRESS were observed.
Keywords
- severe cutaneous adverse drug reactions
- drug reaction with eosinophilia and systematic symptoms
- HLA
- vancomycin
- delayed-type drug hypersensitivity reactions